EX-99.2 3 a12-17045_1ex99d2.htm EX-99.2

Exhibit 99.2

 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1a

 

 

 

2012

 

2011

 

% Change

 

 

 

1Q

 

2Q

 

YTD

 

1Q

 

2Q

 

YTD

 

3Q

 

4Q

 

Full Year

 

2Q

 

YTD

 

Sales

 

$

11,731

 

$

12,311

 

$

24,041

 

$

11,580

 

$

12,151

 

$

23,732

 

$

12,022

 

$

12,294

 

$

48,047

 

1

%

1

%

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

4,037

 

4,112

 

8,150

 

4,059

 

4,284

 

8,343

 

4,352

 

4,176

 

16,871

 

-4

%

-2

%

Marketing and administrative

 

3,074

 

3,249

 

6,322

 

3,164

 

3,525

 

6,689

 

3,340

 

3,704

 

13,733

 

-8

%

-5

%

Research and development

 

1,862

 

2,165

 

4,026

 

2,158

 

1,936

 

4,094

 

1,954

 

2,419

 

8,467

 

12

%

-2

%

Restructuring costs

 

219

 

144

 

363

 

(14

)

668

 

654

 

119

 

533

 

1,306

 

-78

%

-44

%

Equity income from affiliates

 

(110

)

(142

)

(253

)

(138

)

(55

)

(193

)

(161

)

(257

)

(610

)

*

 

31

%

Other (income) expense, net

 

142

 

103

 

247

 

622

 

121

 

744

 

66

 

139

 

946

 

-15

%

-67

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income Before Taxes

 

2,507

 

2,680

 

5,186

 

1,729

 

1,672

 

3,401

 

2,352

 

1,580

 

7,334

 

60

%

52

%

Income Tax Provision (Benefit)

 

740

 

860

 

1,599

 

658

 

(382

)

276

 

628

 

37

 

942

 

 

 

 

 

Net Income

 

1,767

 

1,820

 

3,587

 

1,071

 

2,054

 

3,125

 

1,724

 

1,543

 

6,392

 

-11

%

15

%

Less: Net Income Attributable to Noncontrolling Interests

 

29

 

27

 

56

 

28

 

30

 

58

 

32

 

31

 

120

 

 

 

 

 

Net Income Attributable to Merck & Co., Inc.

 

$

1,738

 

$

1,793

 

$

3,531

 

$

1,043

 

$

2,024

 

$

3,067

 

$

1,692

 

$

1,512

 

$

6,272

 

-11

%

15

%

Earnings per Common Share Assuming Dilution

 

$

0.56

 

$

0.58

 

$

1.15

 

$

0.34

 

$

0.65

 

$

0.98

 

$

0.55

 

$

0.49

 

$

2.02

 

-11

%

17

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Shares Outstanding Assuming Dilution

 

3,074

 

3,072

 

3,074

 

3,104

 

3,110

 

3,106

 

3,091

 

3,069

 

3,094

 

 

 

 

 

Tax Rate

 

29.5

%

32.1

%

30.8

%

38.1

%

-22.8

%

8.1

%

26.7

%

2.3

%

12.8

%

 

 

 

 

 

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

 

*100% or greater

 



 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

SECOND QUARTER 2011

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2c

 

 

 

GAAP

 

Acquisition-
Related Costs 
(1)

 

Restructuring
Costs 
(2)

 

Certain Other
Items

 

Adjustment
Subtotal

 

Non-GAAP

 

Sales

 

$

12,151

 

 

 

 

 

 

 

$

 

$

12,151

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

4,284

 

1,344

 

109

 

 

 

1,453

 

2,831

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and administrative

 

3,525

 

77

 

23

 

 

 

100

 

3,425

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

1,936

 

19

 

16

 

 

 

35

 

1,901

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

668

 

 

 

668

 

 

 

668

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity income from affiliates

 

(55

)

 

 

 

 

 

 

 

(55

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

121

 

 

 

 

 

7

 

7

 

114

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income Before Taxes

 

1,672

 

(1,440

)

(816

)

(7

)

(2,263

)

3,935

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Taxes on Income

 

(382

)

 

 

 

 

 

 

(1,337

)(3)

955

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income

 

2,054

 

 

 

 

 

 

 

(926

)

2,980

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less: Net Income Attributable to Noncontrolling Interests

 

30

 

 

 

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income Attributable to Merck & Co., Inc.

 

$

2,024

 

 

 

 

 

 

 

$

(926

)

$

2,950

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per Common Share Assuming Dilution

 

$

0.65

 

 

 

 

 

 

 

 

 

$

0.95

(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Shares Outstanding Assuming Dilution

 

3,110

 

 

 

 

 

 

 

 

 

3,110

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax Rate

 

-22.8

%

 

 

 

 

 

 

 

 

24.3

%

 

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

 

(1) Amounts included in materials and production costs reflect expenses of $1.2 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as $118 million of impairment charges on product intangibles.  Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company’s formal restructuring programs.  Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

(3) Includes a net benefit of approximately $700 million relating to the settlement of the company’s 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net $230 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

(4) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders.  Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $2,942 million for the second quarter of 2011.

 



 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

 GAAP TO NON-GAAP RECONCILIATION

SIX MONTHS ENDED JUNE 30, 2011

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2d

 

 

 

GAAP

 

Acquisition
Related Costs 
(1)

 

Restructuring
Costs 
(2)

 

Certain Other
Items 
(3)

 

Adjustment
Subtotal

 

Non-GAAP

 

Sales

 

$

23,732

 

 

 

 

 

 

 

$

 

$

23,732

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs, Expenses and Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Materials and production

 

8,343

 

2,641

 

181

 

 

 

2,822

 

5,521

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketing and administrative

 

6,689

 

135

 

46

 

 

 

181

 

6,508

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

4,094

 

321

 

61

 

 

 

382

 

3,712

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restructuring costs

 

654

 

 

 

654

 

 

 

654

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity income from affiliates

 

(193

)

 

 

 

 

 

 

 

(193

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other (income) expense, net

 

744

 

 

 

 

 

373

 

373

 

371

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income Before Taxes

 

3,401

 

(3,097

)

(942

)

(373

)

(4,412

)

7,813

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Taxes on Income

 

276

 

 

 

 

 

 

 

(1,668

)(4)

1,944

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income

 

3,125

 

 

 

 

 

 

 

(2,744

)

5,869

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Less: Net Income Attributable to Noncontrolling Interests

 

58

 

 

 

 

 

 

 

 

58

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Income Attributable to Merck & Co., Inc.

 

$

3,067

 

 

 

 

 

 

 

$

(2,744

)

$

5,811

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per Common Share Assuming Dilution

 

$

0.98

 

 

 

 

 

 

 

 

 

$

1.87

(5)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Shares Outstanding Assuming Dilution

 

3,106

 

 

 

 

 

 

 

 

 

3,106

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tax Rate

 

8.1

%

 

 

 

 

 

 

 

 

24.9

%

 

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

 

(1) Amounts included in materials and production costs reflect expenses of $2.5 billion for the amortization of intangible assets and the amortization of purchase accounting adjustments to inventories recognized as a result of mergers and acquisitions, as well as $118 million of impairment charges on product intangibles.  Amounts included in marketing and administrative expenses reflect integration costs, as well as other costs associated with mergers and acquisitions, such as severance costs which are not part of the company’s formal restructuring programs.  Amounts included in research and development expenses represent in-process research and development (“IPR&D”) impairment charges.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

(3) Included in other (income) expense, net is a $500 million charge related to the resolution of the arbitration proceeding with Johnson & Johnson and a $127 million gain on the sale of certain manufacturing facilities and related assets.

(4) Includes a net benefit of approximately $700 million relating to the settlement of the company’s 2002-2005 federal income tax audit, the favorable impact of certain foreign and state tax rate changes that resulted in a net $230 million reduction of deferred tax liabilities on intangibles established in purchase accounting, as well as the estimated tax impact on the reconciling items.

(5) The company calculates earnings per share pursuant to the two-class method which requires the allocation of net income between common shareholders and participating security holders.  Net income attributable to Merck & Co., Inc. common shareholders used to calculate non-GAAP earnings per common share assuming dilution was $5,795 million for the first six months of 2011.

 



 

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES 

SECOND QUARTER 2012

(AMOUNTS IN MILLIONS)

Table 3a

 

 

 

Global

 

U.S.

 

International

 

 

 

2Q12

 

2Q11

 

% Change

 

2Q12

 

2Q11

 

% Change

 

2Q12

 

2Q11

 

% Change

 

TOTAL SALES (1)

 

$12,311

 

$12,151

 

1

 

$5,555

 

$5,006

 

11

 

$6,756

 

$7,145

 

-5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PHARMACEUTICAL

 

10,560

 

10,360

 

2

 

4,633

 

4,088

 

13

 

5,927

 

6,271

 

-5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Primary Care and Women’s Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zetia

 

632

 

592

 

7

 

330

 

292

 

13

 

301

 

300

 

 

 

Vytorin

 

445

 

459

 

-3

 

195

 

215

 

-9

 

250

 

244

 

2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diabetes & Obesity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Januvia

 

1,058

 

779

 

36

 

532

 

423

 

26

 

525

 

356

 

48

 

Janumet

 

411

 

321

 

28

 

210

 

173

 

22

 

201

 

149

 

35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Respiratory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Singulair

 

1,431

 

1,354

 

6

 

1,002

 

869

 

15

 

429

 

485

 

-12

 

Nasonex

 

293

 

323

 

-9

 

141

 

148

 

-5

 

152

 

175

 

-13

 

Clarinex

 

140

 

209

 

-33

 

54

 

53

 

2

 

86

 

156

 

-45

 

Asmanex

 

51

 

47

 

8

 

46

 

42

 

9

 

5

 

5

 

-6

 

Dulera

 

50

 

25

 

*

 

48

 

25

 

92

 

3

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Women’s Health & Endocrine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fosamax

 

186

 

221

 

-16

 

9

 

15

 

-42

 

177

 

206

 

-14

 

NuvaRing

 

157

 

154

 

2

 

92

 

90

 

2

 

65

 

64

 

1

 

Follistim AQ

 

125

 

143

 

-12

 

47

 

38

 

22

 

78

 

104

 

-25

 

Implanon

 

85

 

81

 

5

 

39

 

33

 

17

 

46

 

48

 

-3

 

Cerazette

 

72

 

66

 

9

 

 

 

 

 

 

 

72

 

66

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Maxalt

 

154

 

131

 

17

 

115

 

82

 

41

 

38

 

49

 

-22

 

Arcoxia

 

117

 

100

 

17

 

 

 

 

 

 

 

117

 

100

 

17

 

Avelox

 

44

 

61

 

-28

 

42

 

55

 

-23

 

2

 

6

 

-71

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospital and Specialty

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Immunology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remicade

 

518

 

842

 

-38

 

 

 

 

 

 

 

518

 

842

 

-38

 

Simponi

 

76

 

75

 

1

 

 

 

 

 

 

 

76

 

75

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Infectious Disease

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Isentress

 

398

 

337

 

18

 

203

 

171

 

19

 

195

 

166

 

17

 

PegIntron

 

183

 

154

 

19

 

24

 

10

 

*

 

159

 

144

 

10

 

Cancidas

 

166

 

168

 

-1

 

7

 

6

 

1

 

159

 

161

 

-1

 

Victrelis

 

126

 

21

 

*

 

68

 

18

 

*

 

58

 

3

 

*

 

Invanz

 

110

 

103

 

7

 

55

 

51

 

8

 

55

 

52

 

6

 

Primaxin

 

104

 

136

 

-24

 

7

 

26

 

-75

 

97

 

110

 

-11

 

Noxafil

 

66

 

56

 

19

 

21

 

12

 

74

 

45

 

44

 

4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Temodar

 

225

 

234

 

-4

 

106

 

96

 

11

 

119

 

138

 

-14

 

Emend

 

145

 

120

 

21

 

73

 

60

 

21

 

73

 

60

 

21

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cosopt / Trusopt

 

105

 

122

 

-14

 

4

 

5

 

-25

 

101

 

117

 

-13

 

Bridion

 

60

 

47

 

27

 

 

 

 

 

 

 

60

 

47

 

27

 

Integrilin

 

60

 

56

 

7

 

54

 

51

 

7

 

5

 

5

 

1

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diversified Brands

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cozaar / Hyzaar

 

337

 

406

 

-17

 

9

 

14

 

-40

 

329

 

392

 

-16

 

Propecia

 

100

 

112

 

-11

 

33

 

33

 

-1

 

68

 

79

 

-15

 

Zocor

 

96

 

107

 

-10

 

7

 

9

 

-23

 

89

 

98

 

-9

 

Claritin Rx

 

48

 

65

 

-27

 

 

 

 

 

 

 

48

 

65

 

-27

 

Remeron

 

66

 

57

 

16

 

1

 

1

 

15

 

64

 

55

 

16

 

Proscar

 

55

 

53

 

4

 

1

 

1

 

53

 

53

 

52

 

3

 

Vasotec / Vaseretic

 

49

 

59

 

-18

 

 

 

 

 

 

 

49

 

59

 

-18

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vaccines

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gardasil

 

324

 

277

 

17

 

224

 

198

 

13

 

101

 

79

 

28

 

ProQuad, M-M-R II and Varivax

 

316

 

291

 

9

 

285

 

270

 

6

 

31

 

21

 

47

 

RotaTeq

 

142

 

148

 

-4

 

102

 

120

 

-15

 

40

 

28

 

44

 

Zostavax

 

148

 

122

 

22

 

137

 

120

 

14

 

11

 

1

 

*

 

Pneumovax

 

101

 

64

 

57

 

85

 

47

 

81

 

16

 

17

 

-8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Pharmaceutical (2)

 

985

 

1,064

 

-7

 

225

 

216

 

4

 

761

 

848

 

-10

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ANIMAL HEALTH

 

865

 

802

 

8

 

238

 

161

 

48

 

628

 

641

 

-2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSUMER CARE

 

552

 

541

 

2

 

383

 

364

 

5

 

169

 

177

 

-4

 

Claritin OTC

 

145

 

134

 

8

 

101

 

93

 

8

 

45

 

41

 

8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Revenues (3)

 

333

 

448

 

-26

 

301

 

393

 

-23

 

32

 

55

 

-42

 

Astra

 

223

 

306

 

-27

 

223

 

306

 

-27

 

 

 

 

 

 

 

 

*

100% or greater

 

(1)  Only select products are shown.

(2)  Includes Pharmaceutical products not individually shown above.  Other Vaccine sales included in Other Pharmaceutical were $75 million and $67 million on a global basis for second quarter 2012 and 2011, respectively.

(3)  Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.

 



 

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

JUNE YEAR-TO-DATE 2012

(AMOUNTS IN MILLIONS)

Table 3b

 

 

 

Global

 

U.S.

 

International

 

 

 

Jun
YTD 12

 

Jun
YTD 11

 

% Change

 

Jun
YTD 12

 

Jun
YTD 11

 

% Change

 

Jun
YTD 12

 

Jun
YTD 11

 

% Change

 

TOTAL SALES (1)

 

$24,041

 

$23,732

 

1

 

$10,565

 

$9,854

 

7

 

$13,477

 

$13,877

 

-3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

PHARMACEUTICAL

 

20,642

 

20,179

 

2

 

8,823

 

7,996

 

10

 

11,819

 

12,184

 

-3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Primary Care and Women’s Health

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cardiovascular

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Zetia

 

1,246

 

1,174

 

6

 

639

 

590

 

8

 

607

 

584

 

4

 

Vytorin

 

889

 

939

 

-5

 

384

 

462

 

-17

 

505

 

477

 

6

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diabetes & Obesity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Januvia

 

1,977

 

1,518

 

30

 

1,025

 

849

 

21

 

952

 

669

 

42

 

Janumet

 

802

 

626

 

28

 

412

 

335

 

23

 

391

 

291

 

34

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Respiratory

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Singulair

 

2,771

 

2,682

 

3

 

1,878

 

1,679

 

12

 

892

 

1,004

 

-11

 

Nasonex

 

668

 

696

 

-4

 

303

 

305

 

-1

 

365

 

391

 

-7

 

Clarinex

 

273

 

364

 

-25

 

105

 

100

 

5

 

168

 

265

 

-36

 

Asmanex

 

99

 

107

 

-8

 

89

 

96

 

-7

 

10

 

11

 

-10

 

Dulera

 

89

 

37

 

*

 

85

 

37

 

*

 

4

 

 

 

*

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Women’s Health & Endocrine

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fosamax

 

370

 

429

 

-14

 

16

 

28

 

-42

 

354

 

401

 

-12

 

NuvaRing

 

303

 

297

 

2

 

175

 

177

 

-1

 

128

 

120

 

6

 

Follistim AQ

 

241

 

276

 

-13

 

85

 

76

 

11

 

156

 

199

 

-22

 

Implanon

 

161

 

141

 

14

 

70

 

58

 

22

 

91

 

83

 

9

 

Cerazette

 

139

 

125

 

11

 

 

 

 

 

 

 

139

 

125

 

11

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Maxalt

 

310

 

304

 

2

 

227

 

214

 

6

 

82

 

90

 

-9

 

Arcoxia

 

229

 

214

 

7

 

 

 

 

 

 

 

229

 

214

 

7

 

Avelox

 

117

 

167

 

-30

 

112

 

152

 

-26

 

5

 

15

 

-69

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Hospital and Specialty

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Immunology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Remicade

 

1,037

 

1,595

 

-35

 

 

 

 

 

 

 

1,037

 

1,595

 

-35

 

Simponi

 

150

 

129

 

16

 

 

 

 

 

 

 

150

 

129

 

16

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Infectious Disease

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Isentress

 

735

 

629

 

17

 

389

 

321

 

21

 

345

 

309

 

12

 

PegIntron

 

345

 

319

 

8

 

56

 

27

 

*

 

289

 

292

 

-1

 

Cancidas

 

311

 

326

 

-4

 

15

 

19

 

-22

 

296

 

307

 

-3

 

Victrelis

 

238

 

22

 

*

 

136

 

18

 

*

 

102

 

4

 

*

 

Invanz

 

211

 

189

 

12

 

106

 

95

 

12

 

105

 

94

 

12

 

Primaxin

 

192

 

272

 

-30

 

11

 

52

 

-78

 

181

 

221

 

-18

 

Noxafil

 

125

 

110

 

13

 

36

 

28

 

29

 

89

 

83

 

8

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Oncology

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Temodar

 

461

 

481

 

-4

 

211

 

198

 

7

 

251

 

283

 

-12

 

Emend

 

247

 

207

 

19

 

135

 

111

 

22

 

112

 

96

 

17

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cosopt / Trusopt

 

229

 

236

 

-3

 

7

 

9

 

-16

 

222

 

227

 

-2

 

Bridion

 

118

 

89

 

33

 

 

 

 

 

 

 

118

 

89

 

33

 

Integrilin

 

113

 

120

 

-6

 

103

 

110

 

-6

 

9

 

10

 

-3

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diversified Brands

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cozaar / Hyzaar

 

674

 

832

 

-19

 

13

 

51

 

-74

 

660

 

781

 

-15

 

Propecia

 

208

 

218

 

-5

 

64

 

65

 

-1

 

144

 

154

 

-6

 

Zocor

 

199

 

234

 

-15

 

13

 

17

 

-23

 

186

 

217

 

-14

 

Claritin Rx

 

134

 

186

 

-28

 

 

 

 

 

 

 

134

 

186

 

-28

 

Remeron

 

123

 

117

 

5

 

3

 

4

 

-20